Sublingual vaccination induces mucosal and systemic adaptive immunity for protection against lung tumor challenge

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Singh, Shailbala ^a   Yang, Guojun ^a   Schluns, Kimberly S ^a,b   Anthony, Scott M ^a,b   Sastry, K Jagannadha ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; OVALBUMIN; ALPHA-GALACTOSYLCERAMIDE; CANCER VACCINE; GALACTOSYLCERAMIDE; IMMUNOLOGICAL ADJUVANT; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; INNATE IMMUNITY; LUNG; LUNG TUMOR; LYMPH NODE; MELANOMA B16; MOUSE; MOUSE MODEL; MUCOSAL IMMUNITY; NATURAL KILLER T CELL; NONHUMAN; SPLEEN; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DENDRITIC CELL; HUMORAL IMMUNITY; IMMUNOLOGY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MOUTH MUCOSA; SECONDARY; SUBLINGUAL DRUG ADMINISTRATION; TUMOR CELL LINE; VACCINATION;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; GALACTOSYLCERAMIDES; IMMUNITY, HUMORAL; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MOUTH MUCOSA; NATURAL KILLER T-CELLS; NEOPLASM TRANSPLANTATION; OVALBUMIN; VACCINATION;

EID: 84897147481     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090001     Document Type: Article

References (42)

1. Moon JH, Chung MK, Son YI (2012) Immunotherapy with dendritic cells in an animal model of early pulmonary metastatic squamous cell carcinoma. Laryngoscope 122: 2442-2446.
2. Patel JK, Didolkar MS, Pickren JW, Moore RH (1978) Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 135: 807-810 (Pubitemid 8377329)
3. Leong SP, Cady B, Jablons DM, Garcia-Aguilar J, Reintgen D, et al. (2006) Clinical patterns of metastasis. Cancer Metastasis Rev 25: 221-232. (Pubitemid 43890716)
4. Nguyen DX, Bos PD, Massague J (2009) Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9: 274-284.
5. Neutra MR, Kozlowski PA (2006) Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6: 148-158. (Pubitemid 43361590)
6. Sandoval F, Terme M, Nizard M, Badoual C, Bureau MF, et al. (2013) Mucosal imprinting of vaccine-induced CD8(+) T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med 5: 172ra120.
7. Lycke N (2012) Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12: 592-605.
8. Naz RK (2012) Female genital tract immunity: distinct immunological challenges for vaccine development. J Reprod Immunol 93: 1-8.
9. Czerkinsky C, Cuburu N, Kweon MN, Anjuere F, Holmgren J (2011) Sublingual vaccination. Hum Vaccin 7: 110-114.
10. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, et al. (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25: 8598-8610. (Pubitemid 350192038)
11. Kweon MN (2011) Sublingual mucosa: A new vaccination route for systemic and mucosal immunity. Cytokine 54: 1-5.
12. Agostinis F, Foglia C, Landi M, Cottini M, Lombardi C, et al. (2008) The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy 63: 1637-1639.
13. Armstrong ME, Lavelle EC, Loscher CE, Lynch MA, Mills KH (2005) Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis 192: 1628-1633. (Pubitemid 41504699)
14. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR (2002) A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20: 2431-2438. (Pubitemid 34615580)
15. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, et al. (2003) Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol 77: 10078-10087. (Pubitemid 37122089)
16. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, et al. (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 350: 896-903. (Pubitemid 38252537)
17. Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, et al. (2011) Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One 6: e26973.
18. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198: 267-279. (Pubitemid 36987852)
19. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, et al. (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 171: 5140-5147. (Pubitemid 37432797)
20. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, et al. (2004) Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J Clin Invest 114: 1800-1811. (Pubitemid 40385536)
21. Brigl M, Brenner MB (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22: 817-890. (Pubitemid 38680443)
22. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN (2004) Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 53: 176-186. (Pubitemid 38328040)
23. Seino K, Taniguchi M (2004) Functional roles of NKT cell in the immune system. Front Biosci 9: 2577-2587.
24. Fraser CK, Lousberg EL, Guerin LR, Hughes TP, Brown MP, et al. (2010) Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biol Ther 10: 715-727.
25. Courtney AN, Nehete PN, Nehete BP, Thapa P, Zhou D, et al. (2009) Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens. Vaccine 27: 3335-3341.
26. Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, et al. (2011) Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol 41: 3312-3322.
27. Matsuo K, Koizumi H, Akashi M, Nakagawa S, Fujita T, et al. (2011) Intranasal immunization with poly(gamma-glutamic acid) nanoparticles entrapping antigenic proteins can induce potent tumor immunity. J Control Release 152: 310-316.
28. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM, Schmieg J, et al. (2002) Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195: 617-624. (Pubitemid 34461506)
29. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, et al. (2005) Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med 201: 1503-1517. (Pubitemid 40664093)
30. Kunii N, Horiguchi S, Motohashi S, Yamamoto H, Ueno N, et al. (2009) Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 100: 1092-1098.
31. Song JH, Nguyen HH, Cuburu N, Horimoto T, Ko SY, et al. (2008) Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 105: 1644-1649. (Pubitemid 351346568)
32. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, et al. (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115: 2572-2583. (Pubitemid 41266220)
33. Uldrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, et al. (2005) NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 175: 3092-3101. (Pubitemid 41170529)
34. Kamijuku H, Nagata Y, Jiang X, Ichinohe T, Tashiro T, et al. (2008) Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses. Mucosal Immunol 1: 208-218. (Pubitemid 351541306)
35. Guillonneau C, Mintern JD, Hubert FX, Hurt AC, Besra GS, et al. (2009) Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. Proc Natl Acad Sci U S A 106: 3330-3335.
36. Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, et al. (2012) Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One 7: e37991.
37. Song JH, Kim JI, Kwon HJ, Shim DH, Parajuli N, et al. (2009) CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination. J Immunol 182: 6851-6860.
38. Mascarell L, Lombardi V, Zimmer A, Louise A, Tourdot S, et al. (2009) Mapping of the lingual immune system reveals the presence of both regulatory and effector CD4+ T cells. Clin Exp Allergy 39: 1910-1919.
39. Hovav AH (2013) Dendritic cells of the oral mucosa. Mucosal Immunol.
40. Hervouet C, Luci C, Bekri S, Juhel T, Bihl F, et al. (2013) Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells. Mucosal Immunol.
41. Choi JH, Schafer SC, Zhang L, Kobinger GP, Juelich T, et al. (2012) A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs. Mol Pharm 9: 156-167.
42. Hervouet C, Luci C, Cuburu N, Cremel M, Bekri S, et al. (2010) Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine 28: 5582-5590.